Clinical trials: Gut
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Obesity
Study of the Gut Hormone Analogue Y14 in Adult Subjects
A randomised, placebo controlled Phase I study to investigate investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Y14 in adult subjects.
- Trial name
- NCT03673111
- Testing
- Y14
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Colorectal Tumor
Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection
The purpose of this study is to address the question of whether or not oral alimentation and ambulation exercise should be begun early in patients following laparoscopic colorectal surgery compared to the classical diet and…
- Trial name
- NCT00606944
- Testing
- fast-track rehabilitation
- Where
- 2 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer Screening
Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
The rate of screening for colorectal cancer (CRC) in the U.S. remains low (under 65%), meaning that thousands of people die of colorectal cancer unnecessarily.
- Trial name
- NCT04683744
- Testing
- Semi-structured interviews-Patients, Semi-structured interviews-Health system
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Indiana University
Ulcerative Colitis, Inflammatory Bowel Disease
A Trial of Rosiglitazone for Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating rosiglitazone: 4 mg tablets or placebo tablets administered orally twice daily for 12 weeks.
- Trial name
- NCT00065065
- Testing
- Rosiglitazone
- Where
- 13 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- James Lewis
Colon Carcinoma, Dysplasia in Crohn Disease
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
This pilot, randomized phase I/II trial studies how well inositol works in preventing colorectal cancer in patients with abnormal cells (dysplasia) associated with inflammation of the colon (colitis).
- Conditions
- Colon Carcinoma, Dysplasia in Crohn Disease, Low Grade Dysplasia in Ulcerative Colitis, Rectal Carcinoma
- Trial name
- NCT01111292
- Testing
- Inositol
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Infections, Rotavirus
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (Rotarix) in the primary vaccination study (102247).
- Trial name
- NCT00420316
- Testing
- Rotarix (primary vaccination study)
- Where
- 15 sites in Finland
- Volunteers
- 1,613 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for…
- Trial name
- NCT04126733
- Testing
- Regorafenib (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bayer
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Colorectal Cancer
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00107315
- Testing
- bevacizumab, capecitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Colorectal Cancer, Rectal Cancer
SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study
A randomized trial to assess the safety and effectiveness of the Colovac in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer.
- Conditions
- Colorectal Cancer, Rectal Cancer, Rectal Tumor, Rectal/Anal
- Trial name
- SAFE-2 (NCT05010850)
- Testing
- Colovac, Stoma Creation
- Where
- 16 sites in United States, Belgium and 1 more
- Volunteers
- 18 people
- Sponsor
- SafeHeal Inc
Obesity
Modulation of the Intestinal Microbiome by a High Protein Diet
The objective of this study is to test and determine whether a high protein diet induces weight loss by modulating the composition and function of the intestinal microbiome in obesity.
- Trial name
- HPD (NCT04812964)
- Testing
- Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass, Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Recurrent Colon Cancer, Recurrent Rectal Cancer
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
This phase II trial is studying dasatinib to see how well it works in treating patients with previously treated metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00504153
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Appendicitis
EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care
Although appendicitis is the most common surgical emergency in children, its diagnosis remains a challenge and thus, emergency department (ED) providers increasingly rely on computed tomography to distinguish appendicitis from…
- Trial name
- Appy-CDS (NCT02633735)
- Testing
- Appy CDS
- Where
- 2 sites in United States
- Volunteers
- 5,940 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Short Bowel Syndrome
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
This study will follow participants who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric participants with Short Bowel Syndrome (SBS).
- Trial name
- NCT02954458
- Testing
- TED, SOC, Syringe
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 61 people
- Sponsor
- Shire
Crohn's Disease
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population.
- Trial name
- SECURE (NCT00844285)
- Testing
- Cimzia
- Where
- 197 sites in United States
- Volunteers
- 3,072 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Abdominal Pain, Gastritis
MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)
This pilot and feasibility study will be first US study to determine if a magnetically controlled capsule (MCC) can effectively visualize the anatomy of the stomach like a more traditional upper endoscopy (EGD).
- Conditions
- Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
- Trial name
- NCT04724291
- Testing
- MAGNET
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- George Washington University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.